U.S. markets closed

MeiraGTx Holdings plc (MGTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.17-0.02 (-0.39%)
At close: 04:00PM EDT
5.27 +0.10 (+1.93%)
After hours: 07:23PM EDT

MeiraGTx Holdings plc

450 East 29th Street
14th Floor
New York, NY 10016
United States

Full Time Employees343

Key Executives

NameTitlePayExercisedYear Born
Dr. Alexandria ForbesCEO, Pres & Director3.05MN/A1965
Mr. Richard Brian Giroux B.A.COO & CFO2.39MN/A1973
Dr. Robert K. Zeldin M.D.Chief Medical Officer1.1MN/A1963
Mr. Robert J. Wollin J.D.Gen. Counsel & Sec.N/AN/A1977
Dr. Stuart Naylor Ph.D.Chief Devel. OfficerN/AN/A1963
Dr. Michel Michaelides M.D.Head of Clinical OphthalmologyN/AN/AN/A
Ms. Christine Elise SheehySr. VP of Global IntegrationN/AN/A1967
Mr. Joel P. BrooksSr. VP of Fin.N/AN/A1959
Mr. Tim RandallSr. VP of Risk & Internal ControlsN/AN/AN/A
Dr. Alastair Leighton Ph.D.Sr. VP of Manufacturing & Supply ChainN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

Corporate Governance

MeiraGTx Holdings plc’s ISS Governance QualityScore as of March 30, 2023 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.